P. Shirkani , A. Shirkani , S.E. Rasouli , R. Daryapour
{"title":"皮下免疫疗法对儿童和成人过敏性疾病的疗效","authors":"P. Shirkani , A. Shirkani , S.E. Rasouli , R. Daryapour","doi":"10.1016/j.reval.2024.104102","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Immunotherapy is the gradual administration of increasing doses of allergens to reduce or eliminate the patient's adverse clinical response following exposure to these allergens. The goal of the current study was to evaluate the effectiveness of subcutaneous immunotherapy in patients with allergic diseases referred to the Bushehr Asthma and Allergy Clinic, Iran.</p></div><div><h3>Materials and methods</h3><p>Patients with respiratory allergic diseases, who had positive skin prick test, randomly enrolled in this observational study and underwent immunotherapy for one year. To evaluate the efficacy of immunotherapy, two questionnaires were completed for all the patients before and one year after the start of immunotherapy, including the Total Nasal Symptom Score (TNSS) and Asthma Control Test (ACT).</p></div><div><h3>Results</h3><p>A total of 878 patients with asthma or allergic rhinitis disorder [53.6% (<em>n</em> <!-->=<!--> <!-->471) male and 46.4% (<em>n</em> <!-->=<!--> <!-->407) female] with a median (IQR) age of 28.0 (12.0–35.0) years were randomly enrolled in this observational study. Five hundred forty-nine patients (64.8%) were over 18 years old and 298 patients (33.9%) were under 18 years old, the age of the other patients was not known. The median (IQR) duration of disease was 84.0 (36.0–138.0) months. Rinithis allergy had most frequent than asthma [39.9% (<em>n</em> <!-->=<!--> <!-->350) vs. 22.2% (<em>n</em> <!-->=<!--> <!-->195), respectively] and 218 patients (24.8%) have both of them. After the treatment, 234 patients (54.5%) completely stop and 26.3% patient (<em>n</em> <!-->=<!--> <!-->113) used less than half of the drugs. The mean TNSS (<em>n</em> <!-->=<!--> <!-->259) and ACT (<em>n</em> <!-->=<!--> <!-->186) scores for patients had significant difference before and after immunotherapy [13.64 vs. 5.68, <em>P</em> <!--><<!--> <!-->0.001; 7.91 vs. 17.43, <em>P</em> <!--><<!--> <!-->0.001, respectively].</p></div><div><h3>Conclusion</h3><p>The mean TNSS and ACT score before and after the treatment significantly improved the patients’ symptoms. To conclude, standard immunotherapy can be effective in patients with moderate to severe allergic rhinitis and mild to moderate persistent allergic asthma to reduce clinical symptoms.</p></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"64 4","pages":"Article 104102"},"PeriodicalIF":0.3000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effectiveness of subcutaneous immunotherapy in allergic diseases of children and adults\",\"authors\":\"P. Shirkani , A. Shirkani , S.E. Rasouli , R. Daryapour\",\"doi\":\"10.1016/j.reval.2024.104102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Immunotherapy is the gradual administration of increasing doses of allergens to reduce or eliminate the patient's adverse clinical response following exposure to these allergens. The goal of the current study was to evaluate the effectiveness of subcutaneous immunotherapy in patients with allergic diseases referred to the Bushehr Asthma and Allergy Clinic, Iran.</p></div><div><h3>Materials and methods</h3><p>Patients with respiratory allergic diseases, who had positive skin prick test, randomly enrolled in this observational study and underwent immunotherapy for one year. To evaluate the efficacy of immunotherapy, two questionnaires were completed for all the patients before and one year after the start of immunotherapy, including the Total Nasal Symptom Score (TNSS) and Asthma Control Test (ACT).</p></div><div><h3>Results</h3><p>A total of 878 patients with asthma or allergic rhinitis disorder [53.6% (<em>n</em> <!-->=<!--> <!-->471) male and 46.4% (<em>n</em> <!-->=<!--> <!-->407) female] with a median (IQR) age of 28.0 (12.0–35.0) years were randomly enrolled in this observational study. Five hundred forty-nine patients (64.8%) were over 18 years old and 298 patients (33.9%) were under 18 years old, the age of the other patients was not known. The median (IQR) duration of disease was 84.0 (36.0–138.0) months. Rinithis allergy had most frequent than asthma [39.9% (<em>n</em> <!-->=<!--> <!-->350) vs. 22.2% (<em>n</em> <!-->=<!--> <!-->195), respectively] and 218 patients (24.8%) have both of them. After the treatment, 234 patients (54.5%) completely stop and 26.3% patient (<em>n</em> <!-->=<!--> <!-->113) used less than half of the drugs. The mean TNSS (<em>n</em> <!-->=<!--> <!-->259) and ACT (<em>n</em> <!-->=<!--> <!-->186) scores for patients had significant difference before and after immunotherapy [13.64 vs. 5.68, <em>P</em> <!--><<!--> <!-->0.001; 7.91 vs. 17.43, <em>P</em> <!--><<!--> <!-->0.001, respectively].</p></div><div><h3>Conclusion</h3><p>The mean TNSS and ACT score before and after the treatment significantly improved the patients’ symptoms. To conclude, standard immunotherapy can be effective in patients with moderate to severe allergic rhinitis and mild to moderate persistent allergic asthma to reduce clinical symptoms.</p></div>\",\"PeriodicalId\":49130,\"journal\":{\"name\":\"Revue Francaise d Allergologie\",\"volume\":\"64 4\",\"pages\":\"Article 104102\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2024-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Francaise d Allergologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877032024003233\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Francaise d Allergologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877032024003233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effectiveness of subcutaneous immunotherapy in allergic diseases of children and adults
Objectives
Immunotherapy is the gradual administration of increasing doses of allergens to reduce or eliminate the patient's adverse clinical response following exposure to these allergens. The goal of the current study was to evaluate the effectiveness of subcutaneous immunotherapy in patients with allergic diseases referred to the Bushehr Asthma and Allergy Clinic, Iran.
Materials and methods
Patients with respiratory allergic diseases, who had positive skin prick test, randomly enrolled in this observational study and underwent immunotherapy for one year. To evaluate the efficacy of immunotherapy, two questionnaires were completed for all the patients before and one year after the start of immunotherapy, including the Total Nasal Symptom Score (TNSS) and Asthma Control Test (ACT).
Results
A total of 878 patients with asthma or allergic rhinitis disorder [53.6% (n = 471) male and 46.4% (n = 407) female] with a median (IQR) age of 28.0 (12.0–35.0) years were randomly enrolled in this observational study. Five hundred forty-nine patients (64.8%) were over 18 years old and 298 patients (33.9%) were under 18 years old, the age of the other patients was not known. The median (IQR) duration of disease was 84.0 (36.0–138.0) months. Rinithis allergy had most frequent than asthma [39.9% (n = 350) vs. 22.2% (n = 195), respectively] and 218 patients (24.8%) have both of them. After the treatment, 234 patients (54.5%) completely stop and 26.3% patient (n = 113) used less than half of the drugs. The mean TNSS (n = 259) and ACT (n = 186) scores for patients had significant difference before and after immunotherapy [13.64 vs. 5.68, P < 0.001; 7.91 vs. 17.43, P < 0.001, respectively].
Conclusion
The mean TNSS and ACT score before and after the treatment significantly improved the patients’ symptoms. To conclude, standard immunotherapy can be effective in patients with moderate to severe allergic rhinitis and mild to moderate persistent allergic asthma to reduce clinical symptoms.
期刊介绍：
La Revue Française d''Allergologie : un véritable forum pour faire connaître des travaux originaux et permettre la diffusion de l''information auprès de toutes les spécialités concernées par les pathologies allergiques. La Revue Française d''Allergologie (8 numéros par an) est au carrefour de nombreuses spécialités - dermatologie, pédiatrie, ORL, pneumologie, ophtalmologie, médecine interne - qui, toutes, ont à traiter des maladies allergiques. Les symptômes des allergies fondés sur des mécanismes communs sont le plus souvent associés et se succèdent chez un même patient. En forte progression depuis 20 ans, les maladies allergiques sont dans l''attente de perfectionnements et d''avancées thérapeutiques qui permettront aux nombreux patients qui en sont atteints de mieux vivre avec leurs allergies. La Revue Française d''Allergologie se veut donc un véritable forum de discussions et d''échanges entre tous les spécialistes confrontés aux pathologies
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
